Domain Therapeutics launches Kaldi Pharma SPV

DOMAIN Therapeutics has recently launched the Kaldi Pharma, a Specific Purpose Vehicle (SPV) for the exclusive development of the company’s A2a/A1 and A2a antagonist programs.

 

Kaldi Pharma aims to exploit the patented series of A2a/A1 and A2a antagonists discovered by Domain Therapeutics in any indication in which inhibiting adenosine constitutes a valuable therapeutic approach. 

 

Recent studies have revealed that combining an A2a antagonist with immune checkpoint blockers enhances the antimetastatic effects.

 

Kaldi Pharma has granted a worldwide license for the development of the A2a/A1 preclinical candidate for Parkinson’s disease to CleveXel Pharma, with which it entered into an agreement to share future revenues on the program. Kaldi Pharma is expected to grant a second license to another partner for the A2a in oncology.

 

Domain Therapeutics, a biopharmaceutical company specializing in the research and early development of new drug candidates targeting G protein-coupled receptors (GPCRs), entrusted the development of a first product to Prexton Therapeutics. With this SPV, the company reaffirms its strategy to advance product development up to clinical proof-of-concept through dedicated entities enabling a flexible approach and optimized value creation of its programs.

 

Pascal Neuville, Domain Therapeutics CEO and Kaldi Pharma president, said: “We are very excited by the creation of Kaldi and by the considerable potential of our novel generation of adenosine antagonists as drugs against Parkinson and cancer. CleveXel is the perfect partner for Kaldi in CNS indications with their solid expertise in preclinical and clinical drug development.”

 

According to CleveXel Pharma president Christian Bloy, “For CleveXel, this partnership with Kaldi paves the way for real development of our company. We are very pleased with this license on the innovative molecule for Parkinson’s disease. CleveXel’s expertise in drug development will undoubtedly add value to this program. We will make this product a flagship project in our portfolio and take it through to clinical development.”